Allurion Technologies Inc (NYSE: ALUR), a company focussed on ending obesity, announced on Tuesday that Somerset NHS Foundation Trust (FT) has pioneers the use of the company's Gastric Balloon, a groundbreaking non-surgical weight loss solution.

This marks the first introduction of the Allurion Program in the NHS, positioning Somerset FT as the first non-private sector organisation globally to adopt the innovative swallowable gastric balloon.

Administered without surgery, endoscopy, or anaesthesia, the balloon, once swallowed, aids in approximately 10-15% body weight loss over four months. Proven to be both safe and effective, the Allurion Balloon addresses the pressing issue of obesity, offering an efficient and cost-effective alternative to traditional bariatric surgery. The program's non-invasive approach aligns with NHS's goals, providing patients with a quick and efficient treatment option that can potentially save significant time and resources for the healthcare system.